Natera, Inc. ($NTRA) Stock Forecast: Down 5.4% Today

What is Natera, Inc.?

Natera Inc. (NTRA) is a diagnostic and research company recognized for its innovative molecular tests in oncology and women's health. The stock show a strong bearish movement today amid recent market highs and positive news related to the company's progress in cancer diagnostics and prenatal testing.

Why is Natera, Inc. going down?

NTRA stock is down 5.4% on Jan 8, 2026 16:20

• Despite recently reaching an all-time high, Natera Inc. (NTRA) experienced a bearish market movement today, possibly due to concerns raised about the stock's valuation compared to its Fair Value.
• The company's financial outlook, supported by positive developments such as the expanded Fetal Focus test and ALTAIR trial results, still harbors uncertainties regarding further reimbursement and guideline wins to counterbalance high expenses.
• The bearish movement may also be influenced by projections of negative net income for the year, despite increased price targets from various firms.
• Investors may be exercising caution regarding the stock's valuation and the company's capacity to convert clinical progress into sustainable financial growth, contributing to the observed bearish market movement today.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

Natera Inc stock hits all-time high at 247.0 USD

Natera Inc. (NTRA) stock has reached a new all-time high of $247.0 USD, driven by strong investor confidence and impressive revenue growth of 38.17% over the past year. Despite the surge, InvestingPro analysis suggests the stock might be overvalued compared to its Fair Value, and analysts anticipate negative net income this year. The company has also made significant strides in cancer diagnostics, leading to increased price targets from Jefferies, TD Cowen, and Canaccord Genuity.

https://www.investing.com/news/company-news/natera-inc-stock-hits-alltime-high-at-2470-usd-93CH-4433283

Expanded Fetal Test and Stronger ALTAIR Signal Could Be A Game Changer For Natera (NTRA)

Natera has launched an expanded 21-gene Fetal Focus non-invasive prenatal test, supported by data showing high sensitivity across inherited conditions. Additionally, new analysis from the ALTAIR trial indicates a statistically significant disease-free survival benefit for Signatera-positive colorectal cancer patients treated with Trifluridine/Tipiracil, which could positively impact Natera's investment narrative and growth expectations. These developments strengthen the clinical story for Natera's molecular tests in oncology and women's health, though the company's financial future still largely depends on securing further reimbursement and guideline wins to offset high R&D and SG&A expenses.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/expanded-fetal-test-and-stronger-altair-signal-could-be-a-ga

Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI

Natera, Inc. announced new data from its ALTAIR trial and other studies will be presented at the 2026 ASCO GI Symposium. The updated ALTAIR analysis showed a statistically significant disease-free survival benefit in Signatera-positive colorectal cancer patients treated with Trifluridine/Tipiracil following a post-hoc blinded central radiographic review. Additionally, a large-scale study indicated that a rapid increase in Signatera levels served as a strong prognostic marker for relapse risk in CRC patients.

https://finance.yahoo.com/news/natera-presents-updated-analyses-altair-002500824.html

NTRA Gains Momentum as Guggenheim Raises Price Target to $270

Guggenheim has reaffirmed its "Buy" rating for Natera (NTRA) and raised the price target from $230.00 to $270.00, representing a 17.39% increase. This adjustment follows other analysts who have also recently increased price targets for NTRA. Natera Inc. is a diagnostic and research company known for its Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Signatera molecular residual disease test, and Prospera for organ transplant rejection.

https://www.gurufocus.com/news/4094919/ntra-gains-momentum-as-guggenheim-raises-price-target-to-270-ntra-stock-news

Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology

Natera has launched an expanded 21-gene Fetal Focus single-gene non-invasive prenatal test (sgNIPT), which can detect a broader range of inherited conditions with high accuracy. The test demonstrated 96% sensitivity and 98% specificity in the blinded prospective EXPAND clinical trial, analyzing cell-free DNA in maternal blood to identify disease-causing variants. This expanded panel provides clinicians with more comprehensive information for pregnant patients who test positive on Natera's Horizon™ carrier screen, especially when the father is unavailable for testing.

https://www.stocktitan.net/news/NTRA/natera-launches-21-gene-fetal-focus-tm-single-gene-nipt-powered-by-v5lz72q8sfen.html

Trending Today

Fortune Brands Innovations Inc. ($FBIN) Stock Forecast: Up 5.4% Today

PulteGroup Inc. ($PHM) Stock Forecast: Up 7.7% Today

Lennar Corporation Class A ($LEN) Stock Forecast: Up 8.6% Today

Intel Corporation ($INTC) Stock Forecast: Up 10.6% Today

Lam Research Corporation ($LRCX) Stock Forecast: Up 7.8% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 5.2% Today

DENTSPLY SIRONA Inc. ($XRAY) Stock Forecast: Up 2.1% Today

KLA-Tencor Corporation ($KLAC) Stock Forecast: Up 5.3% Today

Equity Residential of Beneficial Interest ($EQR) Stock Forecast: Down 4.5% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Up 6.0% Today

Natera, Inc. Price History

08.07.2025 - NTRA Stock was up 16.5%

• Natera (NTRA) reported a Q2 loss but surpassed revenue estimates, indicating strong top-line growth.
• The positive revenue surprise likely boosted investor confidence in the company's long-term growth prospects.
• Investors may be optimistic about Natera's future potential in the genetic testing market, driving the bullish movement in the stock.
• The market may be interpreting the revenue beat as a sign of Natera's ability to capitalize on the growing demand for personalized healthcare solutions, leading to the bullish momentum in the stock.

08.00.2026 - NTRA Stock was down 5.4%

• Despite recently reaching an all-time high, Natera Inc. (NTRA) experienced a bearish market movement today, possibly due to concerns raised about the stock's valuation compared to its Fair Value.
• The company's financial outlook, supported by positive developments such as the expanded Fetal Focus test and ALTAIR trial results, still harbors uncertainties regarding further reimbursement and guideline wins to counterbalance high expenses.
• The bearish movement may also be influenced by projections of negative net income for the year, despite increased price targets from various firms.
• Investors may be exercising caution regarding the stock's valuation and the company's capacity to convert clinical progress into sustainable financial growth, contributing to the observed bearish market movement today.

09.06.2025 - NTRA Stock was up 5.1%

• There was a strong bullish movement in Natera Inc. today.
• The rise in revenues and profits of a competitor in the AI tools and data services sector may have positively influenced market sentiment towards Natera Inc.
• Investors show optimism about Natera Inc.'s potential for revenue growth and improved margins, similar to the success seen by its competitor.
• The increasing adoption of AI technologies in the healthcare and biotechnology industries could be driving positive investor sentiment towards companies like Natera Inc.

06.00.2026 - NTRA Stock was up 6.3%

• The positive outcomes presented at the ASCO GI Symposium from its ALTAIR trial, showcasing significant disease-free survival benefits for colorectal cancer patients, likely contributed to Natera's bullish movement.
• Natera's stock price target was increased to $270 by Guggenheim, along with other analysts' optimistic adjustments, fueling investor confidence.
• The launch of the expanded 21-gene Fetal Focus single-gene non-invasive prenatal test further demonstrates Natera's commitment to innovation and product expansion, attracting more attention from investors.
• Strong revenue growth and positive market sentiment have driven the stock price upwards, overshadowing concerns such as insider selling and reduced stake by Calamos Advisors LLC.

25.01.2025 - NTRA Stock was down 5.1%

• Natera (NTRA) showed significant bearish movement today.
• Comparison with Gilead Sciences (GILD) in the medical stocks sector may have revealed Natera's underperformance, influencing a negative market sentiment.
• Investors are expressing concerns about Natera's competitive position in the sector, potentially impacting its stock price adversely.
• It is likely that Natera encountered specific challenges or setbacks, prompting investors to sell shares and leading to the bearish movement.

16.09.2025 - NTRA Stock was up 5.2%

• Natera has demonstrated impressive performance over the last 5 years, surpassing market performance by 5.63% annually, likely attracting investors seeking high returns.
• The company's emphasis on cutting-edge genetic testing technologies and its market capitalization of $23.35 billion have bolstered investor confidence and a positive market outlook.
• The favorable sentiment surrounding Natera's historical performance and growth prospects could have triggered heightened buying activity, resulting in today's notable bullish movement in the stock.

11.11.2025 - NTRA Stock was down 3.8%

• Insider selling, specifically by company directors and the CEO, could be a reason behind Natera's stock downturn, despite recent positive developments like the acquisition of Foresight Diagnostics and strong Q3 results.
• The acquisition of Foresight Diagnostics for up to $450 million may have raised investor concerns about integration challenges and potential value dilution.
• While institutional investors have significantly increased their positions and analysts have given positive ratings, ongoing insider selling, especially by top management, has created uncertainty and possibly triggered stock sell-offs.
• Despite optimistic analyst outlooks and robust revenue performance, continuous insider selling activities, including by key executives, might have unsettled investors and contributed to the bearish trend in Natera's stock today.

07.10.2025 - NTRA Stock was down 5.0%

• Natera exceeded revenue predictions but faced a notable loss in Q3 earnings, potentially influencing the stock's downturn.
• Worries about Natera's profitability outlook may have prompted investors to sell off the company's shares.
• The combination of uneven performance and a significant earnings shortfall could have eroded investor faith in Natera's future growth, triggering adverse market movements.

20.01.2025 - NTRA Stock was down 5.3%

• Over the past 5 years, Natera has outperformed the market significantly with an average annual return of 36.12%.
• Despite breaking above the 20-day moving average recently, suggesting a positive momentum, the stock saw a bearish movement today.
• The bearish movement may be due to profit-taking by investors or broader market factors affecting the stock negatively.
• Investors should monitor any upcoming developments related to Natera to determine if the bearish trend is a temporary correction or a more sustained shift in market sentiment.

11.01.2025 - NTRA Stock was down 3.4%

• Strong performance by Natera in the past 5 years may have prompted profit-taking by investors, resulting in a decline in the stock.
• Investors who had gained significantly from Natera's stock in the past might have opted to divest, contributing to the downward trend in the stock price.
• The market sentiment appears to have turned bearish possibly due to perceived overvaluation following the impressive performance, leading to a sell-off and the observed decline in stock price today.

23.03.2025 - NTRA Stock was up 5.1%

• Demonstrating a remarkable performance over the last five years, surpassing the market by 19.34% annually, has attracted investors interested in high returns.
• With a focus on genetic testing and a market capitalization of $20.02 billion, Natera holds a prominent position within the biotech sector, instilling confidence in investors.
• The upward trend in NTRA's stock performance today may be linked to the ongoing positive outlook regarding the company's growth potential and market outperformance.

28.01.2025 - NTRA Stock was down 5.5%

• The bearish movement in NTRA today could be attributed to the reported Q4 loss, despite topping revenue estimates.
• Investors may have reacted negatively to the earnings surprise and uncertainties about the company's future profitability.
• The market sentiment might have shifted due to concerns raised by the financial performance, leading to a sell-off of Natera shares.
• The slight miss in earnings and revenue could have caused investors to reassess the stock's valuation and potential growth prospects, resulting in the bearish movement observed today.